Zabedosertib, a novel interleukin-1 receptor-associated kinase-4 inhibitor, shows a favorable pharmacokinetic and safety profile across multiple phase 1 studies. - Feldmüller M; Jodl SJ; Ploeger B; Wagenfeld A; Wiesinger H; Zollmann FS; Klein S; Zhang R; Rohde B; Höchel J (Frontiers in pharmacology, 2025)